Applied Filters
South Korean global licensing spikes n 2018
South Korean pharmaceutical companies entered into 11 out-licensing deals with overseas partners in 2018, according to the country’s Ministry of Health and Welfare.
Sun Pharma buys Japanese company for $1m
India-based drug company Sun Pharma has made further inroads into the Japanese market with the planned acquisition of Pola Pharma.
Scientists want CRISPR regulation amid reports of foetus gene-editing
Scientists have urged policymakers to implement a regulatory framework governing the use of CRISPR technology in humans, following reports that a Chinese scientist has successfully created ‘edited’ twins.
Indian court rules in Sanofi’s favour in trademark suit
The Delhi High Court has ruled against a company for its ‘near identical’ imitation of pharmaceutical company Sanofi’s name and trademarks.
LSPN Europe 2018: Chinese filings impressive statement, says EPO director
Last year, for the first time in European Patent Office history, a Chinese company filed the most European patent applications, making an “impressive statement” on what companies in the country are doing, according to Peter Albrecht.
Australia approves Arrow and Apotex merger
The Australian Competition & Consumer Commission announced yesterday that it has approved the merger of generic drugs companies Arrow and Apotex.
Bombay court finds company liable for infringing Glenmark TM
The Bombay High Court has imposed Rs 1.5 crore of costs on a pharmaceutical company which infringed India-based Glenmark Pharmaceuticals’ trademarks.
Finnegan partner joins Quinn Emanuel in Tokyo
York Faulkner, an IP partner from Finnegan, Henderson, Farabow, Garrett & Dunner, has joined Quinn Emanuel Urquhart & Sullivan in Tokyo.
Astellas boosts ocular pipeline with gene therapy acquisition
Japan-based Astellas Pharma has acquired Quethera, a UK-headquartered gene therapy company focused on developing treatments for ocular disorders.
Samsung to make $22bn investment in new technology
South Korea-based Samsung has revealed plans to commit W25 trillion to pursue new technology in areas including biopharmaceuticals and artificial intelligence.
